Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study

• Published in: Alzheimer's & dementia Vol. 18; no. 12; pp. 2537 - 2550
• Main Authors: Hanon, Olivier, Vidal, Jean‐Sébastien, Lehmann, Sylvain, Bombois, Stéphanie, Allinquant, Bernadette, Baret‐Rose, Christiane, Tréluyer, Jean‐Marc, Abdoul, Hendy, Gelé, Patrick, Delmaire, Christine, Blanc, Fredéric, Mangin, Jean‐François, Buée, Luc, Touchon, Jacques, Hugon, Jacques, Vellas, Bruno, Galbrun, Evelyne, Benetos, Athanase, Berrut, Gilles, Paillaud, Elena, Wallon, David, Castelnovo, Giovanni, Volpe‐Gillot, Lisette, Paccalin, Marc, Robert, Philippe, Godefroy, Olivier, Camus, Vincent, Belmin, Joël, Vandel, Pierre, Novella, Jean‐Luc, Duron, Emmanuelle, Rigaud, Anne‐Sophie, Schraen‐Maschke, Susanna, Gabelle, Audrey
• Format: Journal Article
• Language: English
• Published: United States Alzheimer's Association / Wiley 01.12.2022
• Subjects: Alzheimer Disease - diagnosis; Alzheimer's disease; amyloid beta protein; Amyloid beta-Peptides; Apolipoprotein E4; Biomarkers; cerebrospinal fluid; Cognitive Dysfunction - diagnosis; Disease Progression; Human health and pathology; Humans; Life Sciences; major neurocognitive disorder; mild cognitive impairment; minor neurocognitive disorder; Peptide Fragments; plasma biomarkers; prognosis; tau Proteins; amyloid beta protein; minor neurocognitive disorder; cerebrospinal fluid; plasma biomarkers; mild cognitive impairment; major neurocognitive disorder; Alzheimer's disease; prognosis
• ISSN: 1552-5260; 1552-5279; 1552-5279
• DOI: 10.1002/alz.12613

Introduction Blood‐based biomarkers are the next challenge for Alzheimer's disease (AD) diagnosis and prognosis. Methods Mild cognitive impairment (MCI) participants (N = 485) of the BALTAZAR study, a large‐scale longitudinal multicenter cohort, were followed‐up for 3 years. A total of 165 of them converted to dementia (95% AD). Associations of conversion and plasma amyloid beta (Aβ)1‐42, Aβ1‐40, Aβ1‐42/Aβ1‐40 ratio were analyzed with logistic and Cox models. Results Converters to dementia had lower level of plasma Aβ1‐42 (37.1 pg/mL [12.5] vs. 39.2 [11.1] , P value = .03) and lower Aβ1‐42/Aβ1‐40 ratio than non‐converters (0.148 [0.125] vs. 0.154 [0.076], P value = .02). MCI participants in the highest quartile of Aβ1‐42/Aβ1‐40 ratio (>0.169) had a significant lower risk of conversion (hazard ratio adjusted for age, sex, education, apolipoprotein E ε4, hippocampus atrophy = 0.52 (95% confidence interval [0.31–0.86], P value = .01). Discussion In this large cohort of MCI subjects we identified a threshold for plasma Aβ1‐42/Aβ1‐40 ratio that may detect patients with a low risk of conversion to dementia within 3 years.